Asahi Kasei expands Sonanos with next-gen excipients

Asahi Kasei, a leading healthcare materials provider, is growing its Sonanos™ excipient range. They are adding two new specialty grades. Paid samples are available now, and GMP-compliant products are planned for sale in 2027. Sonanos™ helps make injectable drugs better. It offers sustained release and improved solubility. This is essential for biologics, peptides, and cancer therapies. It’s very important for compounds that don’t dissolve well in water.

The new grades are Sonanos™ PG and Sonanos™ DS.

• Sonanos™ PG is optimized for a steady release of biologics and peptides. This helps with patient-friendly dosing.
• Sonanos™ DS improves the solubility of poorly water-soluble APIs.

These were developed through extensive optimization and experience from over 60 feasibility studies conducted with global pharmaceutical partners since 2020. Both grades are available with guaranteed analytical values for nonclinical development, supporting broader adoption ahead of GMP-compliant production.

こちらもお読みください： Alpha Fusion and Kobe Hospital launch At-211 Drug system

Sonanos™ also supports 旭化成’s spin-out venture, DiveRadGel Inc., which applies the platform to cancer vaccine development, with GMP production of Sonanos™ DV already underway for early-stage clinical trials.